By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MannKind Corporation 

28903 North Avenue Paine

Valencia  California  91355  U.S.A.
Phone: 661-775-5300 Fax: 661-775-2081


SEARCH JOBS

MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas:

  • First, we are continuing to execute the Technosphere® Insulin clinical trial program.
  • Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
  • Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

    Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.

    With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

    Last Updated: 04-01-2008

    Key Statistics


    Email:
    Ownership: Public

    Web Site: MannKind Corporation
    Employees:
    Symbol: MNKD
     









  • Company News
    MannKind Corporation (MNKD) To Present At Upcoming Conferences 5/28/2015 7:25:23 AM
    James S. Shannon Rejoins MannKind Corporation (MNKD)'s Board of Directors 5/21/2015 11:34:16 AM
    MannKind Corporation (MNKD) Reports 2015 First Quarter Financial Results 5/8/2015 8:11:08 AM
    MannKind Corporation (MNKD) To Present At Bank of America (BAC) Merrill Lynch 2015 Healthcare Conference 5/7/2015 12:27:28 PM
    MannKind Corporation (MNKD) To Hold 2015 First Quarter Financial Results Conference Call On May 8, 2015 5/1/2015 8:44:31 AM
    MannKind Corporation (MNKD) To Manufacture 12 Unit Cartridge Strength Of AFREZZA Following FDA Approval 4/27/2015 7:43:25 AM
    MannKind Corporation (MNKD) Reports 2014 Fourth Quarter And Full Year Financial Results 2/25/2015 8:36:26 AM
    MannKind Corporation (MNKD) To Hold 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 24, 2015 2/18/2015 8:20:11 AM
    Sanofi (SAN.PA) And MannKind Corporation (MNKD) Announce Afrezza®, The Only Inhaled Insulin, Now Available In The U.S. 2/3/2015 10:22:17 AM
    Lead Product Afrezza Breathes Life Into MannKind Corporation (MNKD) 1/28/2015 7:25:33 AM
    12345678910...
    //-->